Baer H U, Holzinger F, Feodorovici M, Büchler M W
Klinik für Viszerale und Transplantationschirurgie, Inselspital, Universität Bern.
Ther Umsch. 1998 Feb;55(2):127-33.
Worldwide, hepatocellular carcinoma is one of the most common intra-abdominal malignancy. It occurs mostly in patients who are carriers of the hepatitis B or C virus and/or have liver cirrhosis. There is no screening-test for early recognition of the development of liver cancer and this delays often an accurate diagnosis and early treatment. Resection is the best form of treatment offering a chance of cure. In the last decades, considerable progress has been made in the field of liver diagnostic and operative techniques for liver resection. This has been followed by an increase in the resection rate of patients with malignant liver tumours and by a decrease in postoperative morbidity and mortality. Nowadays, after curative resection, 5-year survival rates up to 30% can be achieved. Promising results are also obtained by new adjuvant therapeutic modalities demonstrating improvement in survival. Therefore, in the field of malignant liver tumours there is no more space for therapeutic nihilismus.
在全球范围内，肝细胞癌是最常见的腹腔内恶性肿瘤之一。它主要发生在乙型或丙型肝炎病毒携带者和/或患有肝硬化的患者中。目前尚无用于早期识别肝癌发展的筛查测试，这常常延误准确诊断和早期治疗。肝切除术是提供治愈机会的最佳治疗方式。在过去几十年中，肝脏诊断和肝切除手术技术领域取得了显著进展。随之而来的是肝恶性肿瘤患者的切除率提高，术后发病率和死亡率降低。如今，根治性切除术后可实现高达30%的5年生存率。新的辅助治疗方式也取得了有希望的结果，显示出生存率有所提高。因此，在恶性肝肿瘤领域，治疗虚无主义已没有立足之地。
